alexa Prediction of Antigenic Peptide and MHC Binder from ITX-3 Tegenaria agrestis: Current Approach for Synthetic Vaccine Development | OMICS International | Abstract
ISSN: 2168-9652

Biochemistry & Physiology: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Prediction of Antigenic Peptide and MHC Binder from ITX-3 Tegenaria agrestis: Current Approach for Synthetic Vaccine Development

Sherkhane AS and Gomase VS*
The Global Open University, Nagaland, India
*Corresponding Author : Gomase VS
The Global Open University, Dimapur-797 112, Nagaland, India
Tel: 91-9987770696
E-mail: [email protected]
Received May 23, 2014; Accepted June 05, 2014; Published June 12, 2014
Citation: Sherkhane AS, Gomase VS (2014) Prediction of Antigenic Peptide and MHC Binder from ITX-3 Tegenaria agrestis: Current Approach for Synthetic Vaccine Development. Biochem Physiol 3:136. doi:10.4172/2168-9652.1000136
Copyright: © 2014 Gomase VS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Venom of Tegenaria agrestis species causes necrosis in humans. ITX-3 is a toxin with 68 amino acids. Antigenic peptides of Tegenaria agrestis toxic protein are most suitable for synthetic peptide vaccine development because with single epitope, the immune response can be generated in large population. In this research, we used PSSM and SVM algorithms for the prediction of MHC class I & II binding peptide, antigenicity, Solvent accessibility, polar and nonpolar residue to analyze the regions that are likely exposed on the surface of proteins which are potentially antigenic that allows potential drug targets to identify active sites as well as to design synthetic peptide vaccine.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7